TY - JOUR
T1 - Quantification of p38αMAP kinase
T2 - A prognostic marker in HNSCC with respect to radiation therapy
AU - Gill, Kamaldeep
AU - Mohanti, Bidhu Kalyan
AU - Ashraf, Md Saquib
AU - Singh, Abhay Kumar
AU - Dey, Sharmistha
N1 - Funding Information:
Authors acknowledge the HNSCC patients those who were involved in this pilot study and Indian Council of Medical Research for providing funds for the consumable items as well as for the fellowship of Kamaldeep Gill. The authors indicate no potential conflict of interest.
PY - 2012/1/18
Y1 - 2012/1/18
N2 - Background: Translation of early findings from basic research is aimed to benefit cancer therapeutics. We report the p38α level in serum of head and neck squamous cell carcinoma (HNSCC) patients indicating it as a prognostic marker and established its correlation with radiation therapy (RT). Methods: The case-controlled study was performed on 120 HNSCC patients from whom 81 patients and 45 controls were statistically analyzed. The p38α estimation was done at pre-RT, during-RT and post-RT using a real time Surface Plasmon Resonance (SPR) technology, ELISA and western blot. Results: HNSCC patients showed threefold increase in p38α level when compared to control (p value < 0.0001). The estimated concentration of p38α in a temporal manner, before-RT, during-RT and post-RT was 0.61. ng/μl (95%CI: 0.53-0.69), 0.35. ng/μl (95%CI: 0.31-0.38) and 0.30. ng/μl (95%CI: 0.26-0.33), respectively. Among the 81 cases, 70 patients (86.42%) showed a declined p38α in response to RT as evaluated by SPR and were responding clinically (clinical tumor regression). Conclusions: This study showed elevated p38α level at cancer diagnosis and a statistically significant decline during-RT and post-RT periods. Hence, it can emerge as a prognostic marker supporting the candidature of p38α as a suitable serum marker in HNSCC.
AB - Background: Translation of early findings from basic research is aimed to benefit cancer therapeutics. We report the p38α level in serum of head and neck squamous cell carcinoma (HNSCC) patients indicating it as a prognostic marker and established its correlation with radiation therapy (RT). Methods: The case-controlled study was performed on 120 HNSCC patients from whom 81 patients and 45 controls were statistically analyzed. The p38α estimation was done at pre-RT, during-RT and post-RT using a real time Surface Plasmon Resonance (SPR) technology, ELISA and western blot. Results: HNSCC patients showed threefold increase in p38α level when compared to control (p value < 0.0001). The estimated concentration of p38α in a temporal manner, before-RT, during-RT and post-RT was 0.61. ng/μl (95%CI: 0.53-0.69), 0.35. ng/μl (95%CI: 0.31-0.38) and 0.30. ng/μl (95%CI: 0.26-0.33), respectively. Among the 81 cases, 70 patients (86.42%) showed a declined p38α in response to RT as evaluated by SPR and were responding clinically (clinical tumor regression). Conclusions: This study showed elevated p38α level at cancer diagnosis and a statistically significant decline during-RT and post-RT periods. Hence, it can emerge as a prognostic marker supporting the candidature of p38α as a suitable serum marker in HNSCC.
KW - Head and neck cancer
KW - P38alpha
KW - Prognostic marker
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=82955163215&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2011.09.031
DO - 10.1016/j.cca.2011.09.031
M3 - Article
C2 - 21982916
AN - SCOPUS:82955163215
SN - 0009-8981
VL - 413
SP - 219
EP - 225
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 1-2
ER -